Retro Biosciences vs PhaseV
Side-by-side comparison of AI visibility scores, market position, and capabilities
Largest-funded pure-play longevity startup raising $1B Series A at $5B valuation; Sam Altman-backed; pursuing cellular reprogramming, autophagy, and plasma factor therapeutics in parallel; first human trial targeting Australia launch.
About
Retro Biosciences is the largest-funded pure-play longevity company in history, raising $1 billion in Series A financing at a $5 billion valuation with Sam Altman (OpenAI CEO) as a primary backer. The company is pursuing cellular reprogramming, autophagy enhancement, and plasma factor therapeutics in parallel — a multi-pronged approach to extending healthy human lifespan by targeting the cellular hallmarks of aging simultaneously.
Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of world's top pharma companies as partners.
About
PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic efficiency improvements over traditional trial execution. The company raised $50 million in Series A financing in May 2025 co-led by Accel and Insight Partners, and entered 2026 with 40+ global pharmaceutical sponsors as customers including 7 of the world's top pharmaceutical companies.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.